PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: A key step in parkinsonism physiopathology

Neurobiology of Disease

Volumn 43, Issue 1, 2011, Pages 293-303

  Giorgi, M ^a   Melchiorri, G ^b   Nuccetelli, V ^a   D'Angelo, V ^b   Martorana, A ^b,c   Sorge, R ^b   Castelli, V ^a   Bernardi, G ^b,c   Sancesario, G ^b,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

6 OHDA; A2A receptors; Basal ganglia; Caudate putamen; CGMP; Globus pallidus; Parkinson's disease; Phosphodiesterase; Substantia nigra; Synaptic plasticity

Indexed keywords

CYCLIC AMP; CYCLIC GMP; MESSENGER RNA; OXIDOPAMINE; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CATABOLISM; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE ACTIVITY; GENE EXPRESSION; GLOBUS PALLIDUS; HEMISPHERE; MALE; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; NEUROPIL; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEUS ACCUMBENS; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RAT; SENSORIMOTOR CORTEX; STEADY STATE; SUBSTANTIA NIGRA PARS RETICULATA; UPREGULATION; VENTRAL TEGMENTUM;

ANIMALS; CYCLIC AMP; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION REGULATION; MALE; METABOLISM; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; NUCLEUS ACCUMBENS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 79955945166     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.04.006     Document Type: Article

References (55)

1. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75:725-748.
2. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
3. Chalimoniuk M., Lagfort J., Lukacova N., Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem. Biophys. Res. Commun. 2004, 324:118-126.
4. Chalimoniuk M., Lukacova N., Marsala J., Langfort J. Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience 2006, 141:1033-1046.
5. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol. 2010, 185:1230-1237.
6. Cooper D.M.F. Molecular and cellular requirements for the regulation of adenylate cyclases by calcium. Biochem. Soc. Trans. 2003, 31:912-915.
7. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
8. Duvoisin R.C. Antagonism of levodopa by papaverine. JAMA 1975, 231:845.
9. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997, 20:482-487.
10. Fisone G., Borgkvist A., Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell. Mol. Life Sci. 2004, 61:857-872.
11. Fourcaudot E., Gambino F., Humeau Y., Casassus G., Shaban H., Poulain B., Luthi A. cAMP/PKA signaling and RIM1_ mediate presynaptic LTP in the lateral amygdale. Proc. Natl Acad. Sci. U. S. A. 2008, 105:15130-15135.
12. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 1999, 274:18438-18445.
13. Fujishige K., Kotera J., Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur. J. Biochem. 1999, 266:1118-1127.
14. Gao F., Sugita M., Nukui H. Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain. Neurol. Res. 2005, 27:638-643.
15. Garau L., Govoni S., Stefanini E., Trabucchi M., Spano P.F. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 1978, 23:1745-1750.
16. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432.
17. German D.C., Manaye K., Smith W.K., Woodward D.J., Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 1989, 26:507-514.
18. Giorgi M., D'Angelo V., Esposito Z., Nuccetelli V., Sorge R., Martorana A., et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur. J. Neurosci. 2008, 28:941-950.
19. Guidotti A., Cheney D.L., Trabucchi M., Doteuch M., Wang C. Focused microwave radiation: a technique to minimize post mortem changes of cyclic nucleotides, dopa and choline and to preserve brain morphology. Neuropharmacology 1974, 13:115-122.
20. Hossain M.A., Weiner N. Dopaminergic functional supersensitivity: effect of L-dopa and carbidopa treatment in an animal model of Parkinson's disease. J. Pharmacol. Exp. Ther. 1993, 267:1105-1111.
21. Kebabian J.W. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase. Life Sci. 1978, 23:479-483.
22. Koesling D., Bohme E., Schultz G. Guanylyl cyclase, a growing family of signal-transducing enzymes. FASEB J. 1991, 5:2785-2791.
23. Kohara K., Ogura A., Akagawa K., Yamaguchi K. Increase in number of functional release sites by cyclic AMP-dependent protein kinase in cultured neurons isolated from hippocampal dentate gyrus. Neurosci. Res. 2001, 41:79-88.
24. Kotera J., Sasaki T., Kobayashi T., Fujishige K., Yamashita Y., Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMPdependent protein kinase-dependent phosphorylation. J. Biol. Chem. 2004, 279:4366-4375.
25. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl Acad. Sci. U. S. A. 1995, 92:1719-1723.
26. Lowry O.H., Rosebrough N.J., Farr A.L. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 1993:265-275.
27. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109:366-398.
28. Lust D.W., Passonneau J.V., Veech R.L. Cyclic adenosine monophosphate, metabolites, and phosphorilase in neural tissue: a comparison of methods of fixation. Science 1973, 181:280-282.
29. Menniti F.S., Chappie T.A., Humphrey J.M., Schmidt C.J. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr. Opin. Investig. Drugs 2007, 8:54-59.
30. Morissette M., Goulet M., Grondin R., Blanchet P., Bedard P.J., Di Paolo T., Levesque D. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci. 1998, 10:2565-2573.
31. Moulder K.L., Jiang X., Chang C.Y., Taylor A.A., Benz A.M., Conti A.C., et al. A specific role for Ca2+-dependent adenylyl cyclases in recovery from adaptive presynaptic silencing. J. Neurosci. 2008, 28:5159-5168.
32. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 1996, 16:2365-2372.
33. Nishi A., Kuroiwa M., Miller D.B., O'Callaghan J.P., Bateup H.S., Shuto T., et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 2008, 28:10460-10471.
34. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temiño B., Mena-Segovia J., et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol. 2008, 64(Suppl 2):S30-S46.
35. Paxinos G., Watson C.R. The Rat Brain in Stereotaxic Coordinates 1992, Raven Press, London.
36. Polli J.W., Kincaid R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci. 1994, 14:251-261.
37. Ryoo H.L., Pierrotti D., Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 1998, 13:788-797.
38. Salmi P., Chergui K., Fredholm B.B. Adenosine-dopamine interactions revealed in knockout mice. J. Mol. Neurosci. 2005, 26:239-244.
39. Sancesario G., Giorgi M., D'Angelo V., Modica A., Martorana A., Morello M., et al. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur. J. Neurosci. 2004, 20:989-1000.
40. Schwarting R.K.W., Huston J.P. Unilateral 6-OHDA lesions of the meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 1996, 49:215-266.
41. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003, 985:113-126.
42. Siuciak J.A., McCarthy S.A., Chapin D.S., Fujiwara R.A., James L.C., Williams R.D., et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006, 51:374-385.
43. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51:386-396.
44. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 2000, 12:174-179.
45. Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 1998, 273:15553-15558.
46. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl Acad. Sci. U. S. A. 1999, 96:7071-7076.
47. Strome E.M., Zis A.P., Doudet D.J. Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J. Psychiatry Neurosci. 2007, 32:193-202.
48. Tenn C.C., Niles L.P. Sensitization of G protein-coupled benzodiazepine receptors in the striatum of 6-hydroxydopamine-lesioned rats. J. Neurochem. 1997, 69:1920-1926.
49. Thompson W.J., Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971, 10:311-316.
50. Threlfell S., Sammut S., Menniti F.S., Schmidt C.J., West A.R. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther. 2009, 328:785-795.
51. Uhl G.R., Hedreen J.C., Price D.L. Parkinson's disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985, 35:1215-1218.
52. Wedel B.J., Garbers D.L. The guanylyl cyclase family at Y2K. Annu. Rev. Physiol. 2001, 63:215-233.
53. Xie Z., Adamowicz O., Eldred W.D., Jakowski A.B., Kleiman R.J., Morton D.G., et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006, 139:597-607.
54. Yagil S., Yoshikawa E., Futatsubashi M., Yokokura M., Yoshihara Y., Torizuka T., et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J. Nucl. Med. 2010, 51:1250-1257.
55. Zhao A.Z., Yan C., Sonnenburg W.K., Beavo L.A. Recent advances in the study of Ca+2 / activated phosphodiesterase. Adv. Second Messenger Phosphoprotein Res. 1997, 31:237-251.